Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain

Inclusion criteria

• Patients with a diagnosis of allergy to cow's milk protein (CMPA): either confirmed through a placebo-controlled food challenge (DBPCFC) or highly suspected based on specific suggestive symptoms;
• Patients under the age of 1 year at the time of cow's milk protein allergy diagnosis.
• Patients taken Damira 2000 for at least 4 months at the time of data extraction.
• Patients with information available on child growth (weight and height) and the following anthropometric indices at diagnosis and for at least 2 follow-up visits after first hospital visit/4 months*: Z-scores for weight-for-age (WAZ), height-for-age (HAZ), weight-for-height (WHZ) and body mass index (BMI)-for-age (BAZ).

Exclusion criteria

• Patients who used other infant formulae or breast milk in addition to the study product of interest during the retrospective study period.
• Premature children with a low birth-weight (<2.5 kg).
• Patients diagnosed with a metabolic condition that impacts development and growth.
• Patients diagnosed with a congenital condition and/or with prior or current disease that in the opinion of the investigator could potentially interfere with the aim of the study.